Obesity and lipoprotein metabolism

Handbook of Obesity: Etiology and Pathophysiology, Second Edition

Volumn , Issue , 2003, Pages 845-871

  Després, Jean Pierre ^a   Krauss, Ronald M ^b,c  

^a LAVAL UNIVERSITY   (Canada)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057487864     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (179)

1. Keys A. Coronary heart disease in seven countries. Circulation 1970; 41(suppl I):I1-I211.
2. WHO Expert Committee on the Prevention of Coronary Heart Disease. World Health Organization Technical Reports Series 678. Geneva: World Health Organization, 1982.
3. NIH Consensus Conference. Lowering blood cholesterol to prevent heart disease. JAMA 1985; 253:2080–2086.
4. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous or graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256:2823–2828.
5. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary heart disease. Am J Cardiol 1991; 67:1185–1189.
6. Sniderman AD, Silberberg J. Is it time to measure apolipoprotein B? Arteriosclerosis 1990; 10(5):665–667.
7. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2001; 104(10):1108–1113.
8. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM Experience). Am J Cardiol 1992; 70:733–737.
9. Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais G, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease-prospective results from the Quebec Cardiovascular Study. Am J Cardiol 1995; 75:1189–1195.
10. Castelli WP. Epidemiology of coronary heart disease: the Framingham Study. Am J Med 1984; 76:4–12.
11. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20):1615–1622.
12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20):1301–1307.
13. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
14. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001–1009.
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The LongTerm Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19):1349–1357.
16. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
17. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153(2):263–272.
18. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996; 94(10):2351–2354.
19. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977; 62:707–714.
20. Miller NE, Forde OH, Thelle DS, Mjos OD. The Tromso Heart Study: high-density lipoprotein as a protective factor against coronary heart disease: a prospective case-control study. Lancet 1977; 1:965–967.
21. Castelli WP, Doyles JT, Gordon T. HDL-cholesterol and other lipids in coronary heart disease: the cooperative lipoprotein phenotyping study. Circulation 1977; 55:767–772.
22. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol 2001; 88(12A): 9N-13N.
23. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341(6):410–418.
24. Rubin EM, Krauss RM, Spangler E, Verstuyft S, Clift S. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991; 353:265–267.
25. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11:1–14.
26. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mäntärri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL-cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37–45.
27. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997; 17(6): 1114–1120.
28. Glomset JA. The plasma lecithin: cholesterol acyltransferase reaction. J Lipid Res 1968; 9:155–167.
29. Trigatti B, Rigotti A, Krieger M. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr Opin Lipidol 2000; 11(2):123–131.
30. Oram JF, Vaughan AM. ABCAl-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr Opin Lipidol 2000; 11(3):253–260.
31. Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001; 11(3-4):155–161.
32. Lamarche B, Despres JP, Pouliot MC, Prud'homme D, Moorjani S, Lupien PJ, Nadeau A, Tremblay A, Bouchard C. Metabolic heterogeneity associated with high plasma triglyceride or low HDL cholesterol levels in men. Arterioscler Thromb 1993; 13(1):33–40.
33. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595–1607.
34. Laakso M, Sarlund H, Mykkanen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 1990; 10:223–231.
35. Reaven GM, Ida-Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92:141–146.
36. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486–2497.
37. Despres JP. Visceral obesity: a component of the insulin resistance-dyslipidemic syndrome. Can J Cardiol 1994; 10:17B-22B.
38. Despres JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994; 5:274–289.
39. Tchernof A, Lamarche B, Prud'homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Despres JP. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996; 19(6):629–637.
40. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A, Despres JP. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyper apolipoprotein B; small, dense LDL) in men? Circulation 2000; 102(2):179–184.
41. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease. Circulation 1990; 82:495–506.
42. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3):356–359.
43. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais G, Despres JP. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996; 94(3):273–278.
44. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from the two population studies in Finland. Diabetes Care 1979; 2:131–141.
45. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2:154–160.
46. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Rosselin G. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res 1985; 15(suppl):41–46.
47. Yarmell JWG, Sweetnam PM, Marks V, Teale JD, Bolton CH. Insulin in ischemic heart disease: are associations explained by triglyceride concentrations? The Caerphilly Prospective Study. Br Heart J 1994; 171: 61 293–296.
48. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32:300–304.
49. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JM, Warnet JM, Rosselin GE, Eschwege E. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study. 15-year follow-up. Diabetologia 1991; 34:356–361.
50. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952–957.
51. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95:69–75.
52. St-Pierre AC, Ruel IL, Cantin B, Dagenais GR, Bernard PM, Despres JP, Lamarche B. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001; 104(19):2295–2299.
53. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Fasting insulin and apolipoprotein B levels and low-density lipoprotein Despres and Krauss particle size as risk factors for ischemic heart disease. JAMA 1998; 279:1955–1961.
54. Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. Med Clin North Am 1989; 73:111–138.
55. Despres JP. Obesity and lipid metabolism: relevance of body fat distribution. Curr Opin Lipidol 1991; 2:515.
56. Despres JP. Dyslipidemia and obesity. Bailleres Clin Endocrinol Metab 1994; 8:629–660.
57. Barrett-Connor E. Obesity, atherosclerosis, and coronary artery disease. Ann Intern Med 1985; 103:1010–1019.
58. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med 1995; 333:677–685.
59. Bouchard C, Despres JP. Variation in fat distribution with age and health implications. In: Eckert HM, Spirduso W, eds. Physical Activity and Aging. Champaign, IL: American Academy of Physical Education, 1989:78–106.
60. Bray GA, Davidson MB, Drenick EJ. Obesity: a serious symptom. An Intern Med 1972; 77:779–795.
61. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chron Dis 1978; 31:201.
62. Bjorntorp P. Hazards in subgroups of human obesity. Eur J Clin Invest 1984; 14:239–241.
63. Harrison GH. Height-weight tables. Ann Intern Med 1985; 103:989–994.
64. Despres JP. Assessing obesity: beyond the BMI. NIN Rev 1992; 7(suppl):1–4.
65. Quetelet LAJ. Sur l'homme et le dévéloppement de ses facultés, ou essai d'une physique sociale Paris: Bachelier, 1835.
66. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chron Dis 1972; 25:329–334.
67. Garrow J, Summerbell C. Meta-analysis on the effect of exercise on the composition of weight loss. Int J Obes 1994; 18:516–517.
68. Bray GA, Gray DS. Treatment of obesity: an overview. Diabetes Metab Rev 1988; 4:653–679.
69. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10:487–511.
70. Kissebah AH, Peiris AN. Biology of regional body fat distribution: Relationship to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1989; 5:83–109.
71. Bjorntorp P. Abdominal obesity and the development of non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1988; 4:615–622.
72. Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K. Central obesity and coronary heart disease in men. Lancet 1987; 1:821–824.
73. Vague J. La differentiation sexuelle, facteur determinant des formes de l'obesite. Presse Med 1947; 30:339–340.
74. Albrink MJ, Meigs JW. Interrelationship between skinfold thickness, serum lipids and blood sugar in normal men. Am J Clin Nutr 1964; 15:255–261.
75. Allard C, Goulet C. Serum lipids: an epidemiological study of an active Montreal population. Can Med Assoc J 1968; 98:627–637.
76. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984; 289:1261–1263.
77. Larsson B, Svardsudd K, Welin L, Wilhemsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity and risk ofcardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. BMJ 1984; 288:1401–1404.
78. Ducimetiere P, Richard J, Cambien F. The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris Prospective Study. Int J Obes 1986; 10:229–240.
79. Ohlsson LO, Larsson B, Svärdsudd K, Welin L, Eriksson H, Wilhelmsen L, Bjorntorp P, Tibblin G. The influence of body fat distribution on the incidence of diabetes mellitus—13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985; 34:1055–1058.
80. Anderson AJ, Sobocinski KA, Freedman DS, Barboriak JJ, Rimm AA, Gruchow HW. Body fat distribution, plasma lipids and lipoproteins. Arteriosclerosis 1988; 8:88–94.
81. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54:254–260.
82. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983; 72:1150–1162.
83. Albrink MJ, Krauss RM, Lindgren FT, Von der Groeben J, Pam S, Wood PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids 1980; 15:668–676.
84. Ostlund RE, Staten M, Kohrt WM, Schultz J, Malley M. The ratio of waist-to-hip circumferences, plasma insulin level, and glucose intolerance as independent predictors of the HDL2-cholesterol level in older adults. N Engl J Med 1990; 322:229–234.
85. Terry RB, Wood PD, Haskell WL, Stefanick ML, Krauss RM. Regional adiposity pattern in relation to lipids, lipoprotein cholesterol, and lipoprotein subfraction mass in men. J Clin Endocrinol Metab 1989; 68: 191–199.
86. Després JP, Moorjani S, Ferland M, Tremblay A, Lupien PJ, Nadeau A, Pinault S, Theriault G, Bouchard C. Adipose tissue distribution and plasma lipoprotein levels in obese women: importance of intra-abdominal fat. Arteriosclerosis 1989; 9: 203–210.
87. Després JP, Ferland M, Moorjani S, Tremblay A, Lupien PJ, Theriault G, Bouchard C. Role of hepatic- triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL-cholesterol in obese women. Arteriosclerosis 1989; 9:485–492.
88. Després JP, Moorjani S, Tremblay A, Ferland M, Lupien PJ, Nadeau A, Bouchard C. Relation of high plasma triglyceride levels associated with obesity and regional adipose tissue distribution to plasma lipoprotein-lipid composition in premenopausal women. Clin Invest Med 1989; 12:374–380.
89. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917–1921.
90. Hartz AJ, Rupley DC, Kalkhoff RD, Rimm AA. Relationship of obesity to diabetes: Influence of obesity and body fat distribution. Prevent Med 1983; 12:351–357.
91. Williams PT, Haskell WL, Vranizan KM, Krauss RM. The associations of high-density lipoprotein subclasses with insulin and glucose levels, physical activity, resting heart rate, and regional adiposity in men with coronary artery disease: the Stanford Coronary Risk Intervention Project baseline survey. Metabolism 1995; 44(1): 106–114.
92. Pascot A, Lemieux I, Prud'homme D, Tremblay A, Nadeau A, Couillard C, Bergeron J, Lamarche B, Després JP. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001; 42(12):2007–2014.
93. Katzel LI, Krauss RM, Goldberg AP. Relation of plasma TG and HDL-C concentrations to body composition and plasma insulin levels are altered in men with small LDL particles. Arterioscler Thromb 1994; 14:1121–1128.
94. Landin K, Lonnroth P, Krotkiewski G, Smith U. Increased insulin resistance and fat cell lipolysis in obese but not lean women with a high waist/hip ratio. Eur J Clin Invest 1990; 20:530–535.
95. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes mellitus in Mexican Americans predicted by fasting insulin and glucose levels, obesity and body fat distribution. Diabetes 1990; 39:283–289.
96. Peiris AN, Struve MF, Kissebah AH. Relationship of body fat distribution to the metabolic clearance of insulin in premenopausal women. Int J Obes 1987; 11: 581–589.
97. Kannel WB, Gordon T, Castelli WP. Obesity, lipids and glucose intolerance. The Framingham Study. Am J Clin Nutr 1979; 32:1238–1245.
98. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982; 36:172–177.
99. Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S. A novel technique for the determination of body fat by computed tomography. Int J Obes 1983; 7:437–445.
100. Sjostrom L, Kvist H, Cederblad A, Tylen U, Sjostrom L, Kvist H, Cederblad A, Tylen U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. Am J Physiol 1986; 250:E736-E745.
101. Kvist H, Chowdhury B, Grangard U, Tylen U, Sjostrom L. Total and visceral adipose tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am J Clin Nutr 1988; 48:1351–1361.
102. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36:54–59.
103. Fujioka S, Matsuzawa Y, Tokunaga K, Kano Y, Kobatake T, Tarui S. Treatment of visceral obesity. Int J Obes 1991; 15:59–65.
104. Fujioka S, Matsuzawa Y, Tokunaga K, Kawamoto T, Kobatake T, Keno Y, Kotani K, Yoshida S, Tarui S. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. Int J Obes 1991; 15:853–859.
105. Sparrow D, Borkan GA, Gerzof SG, Wisniewski CK. Relationship of body fat distribution to glucose tolerance. Results of computed tomography in male participants of the normative aging study. Diabetes 1986; 35:411–415.
106. Peiris AN, Sothmann MS, Hennes MI, Lee MB, Wilson CR, Gustafson AB, Kissebah AH. Relative contribution of obesity and body fat distribution to alterations in glucose insulin homeostasis: predictive values of selected indices in premenopausal women. Am J Clin Nutr 1989; 49:758–764.
107. Després JP, Nadeau A, Tremblay A, Ferland M, Lupien PJ. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989; 38: 304–309.
108. Pouliot MC, Després JP, Nadeau A, Moorjani S, Prud'homme D, Lupien PJ, Tremblay A, Bouchard C. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992;41:826–834.
109. Després JP. Visceral obesity, insulin resistance, and related dyslipoproteinemias. In: Rifkin H, Colwell JA, Taylor SI, eds. Diabetes 1991. Amsterdam: Elsevier Science, 1991:95–99.
110. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Després JP. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr 1993; 58:463–467.
111. Lemieux S, Després JP, Moorjani S, Nadeau A, Theriault G, Prud'homme D, Tremblay A, Bouchard C, Lupien PJ. Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue? Diabetologia 1994; 37:757–764.
112. Després JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev 1993; 6:137–159.
113. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60:473–485.
114. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988; 29:469–479.
115. Krasinski SD, Cohn JS, Schaefer EJ, Russell RM. Postprandial plasma retinyl ester response is greater in older subjects compared with younger subjects. Evidence for a delayed plasma clearance of intestinal lipoproteins. J Clin Invest 1990; 85:883–892.
116. Couillard C, Bergeron N, Prud'homme D, Bergeron J, Tremblay A, Bouchard C, Mauriege P, Després JP. Gender difference in postprandial lipemia-importance of visceral adipose tissue accumulation. Arterioscler Thromb Vasc Biol 1999; 19(10):2448–2455.
117. Georgopoulos A, Rosengard AM. Abnormalities in the metabolism of postprandial and fasting triglyceride-rich lipoprotein subfractions in normal and insulindependent diabetic subjects: effects of sex. Metabolism 1989; 38:781–789.
118. Bergeron N, Havel RJ. Assessment of postprandial lipemia: nutritional influences. Curr Opin Lipidol 1997; 8:43–52.
119. Hartung GH, Lawrence SJ, Reeves RS, Foreyt JP. Effect of alcohol and exercise on postprandial lipemia and triglyceride clearance in men. Atherosclerosis 1993; 100:33–40.
120. Frase AG, Rosalki SB, Gamble GD, Pounder RE. Inter-individual and intra-individual variability of ethanol concentration-time profiles: comparison of ethanol ingestion before or after an evening meal. Br J Clin Pharmacol 1995; 40:387–392.
121. Pownall HJ. Dietary ethanol is associated with reduced lipolysis of intestinally derived lipoproteins. J Lipid Res 1994; 35:2105–2113.
122. Weintraub MS, Rosen Y, Otto R, Eisenberg S, Breslow JL. Physical exercise conditioning in the absence of weight loss reduces fasting and postprandial triglyceride-rich lipoprotein levels. Circulation 1989; 79:1007–1014.
123. Ziogas GG, Thomas TR, Harris WS. Exercise training, postprandial hypertriglyceridemia and LDL subfraction distribution. Med Sci Sports Exerc 1997; 29:986–991.
124. Aldred HE, Perry IC, Hardman AE. The effect of a single bout of brisk walking on postprandial lipemia in normolipidemic young adults. Metabolism 1994; 43: 836–841.
125. Aldred HE, Hardman AE, Taylor S. Influence of 12 weeks of training by brisk walking on postprandial lipemia and insulinemia in sedentary middle-aged women. Metabolism 1995; 44:390–397.
126. Lewis GF, O'Meara NM, Soltys PA, Blackman JD, Iverius PH, Druetzler AF, Getz GS, Polonsky KS. Postprandial lipoprotein metabolism in normal and obese subjects: comparison after the vitamin A fat- loading test. J Clin Endocrinol Metab 1990; 71:1041–1050.
127. Wideman L, Kaminsky LA, Whaley MH. Postprandial lipemia in obese men with abdominal fat patterning. J Sports Med Phys Fitness 1996; 36:204–210.
128. Ryu JE, Craven TE, MacArthur RD, Hinson WH, Bond MG, Hagaman AP, Crouse JR. Relationship of intraabdominal fat as measured by magnetic resonance imaging to postprandial lipemia in middle-aged subjects. Am J Clin Nutr 1994; 60:586–591.
129. Mekki N, Christofilis MA, Charbonnier M, Atlan-Gepner C, Defoort C, Juhel C, Borel P, Portugal H, Pauli AM, Vialettes B, Lairon D. Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women. J Clin Endocrinol Metab 1999; 84(1):184–191.
130. Couillard C, Bergeron N, Prud'homme D, Bergeron J, Tremblay A, Bouchard C, Mauriege P, Després JP. Postprandial triglyceride response in visceral obesity in men. Diabetes 1998; 47(6):953–960.
131. Couillard C, Bergeron N, Bergeron J, Pascot A, Mauriege P, Tremblay A, Prud'homme D, Bouchard C, Després JP. Metabolic heterogeneity underlying postprandial lipemia among men with low fasting high density lipoprotein cholesterol concentrations. J Clin Endocrinol Metab 2000; 85:4575–4582.
132. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78(1):656–660.
133. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Aterioscler Thromb Vasc Biol 1999; 19: 972–978.
134. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Després JP. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21(6):961–967.
135. Tracy RP. Is visceral adiposity the “enemy within”? Arterioscler Thromb Vasc Biol 2001; 21(6):881–883.
136. Després JP. Health consequences of visceral obesity. Ann Med 2001; 33(8):534–541.
137. Bjorntorp P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10:493–496.
138. Hennes M, Shrago E, Kissebah AH. Receptor and post receptor effects of FFA on hepatocyte insulin dynamics. Int J Obes 1990; 14:831–841.
139. Svedberg J, Bjorntorp P, Smith V, Lonnroth P. FFA inhibition of insulin binding, degradation, and action in isolated rat hepatocytes. Diabetes 1990; 39:570–574.
140. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle; its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1:785–789.
141. Taylor SI, Mukherjee C, Jungas RL. Regulation of pyruvate dehydrogenase in isolated rat liver mitochondria. J Biol Chem 1975; 250:2028–2035.
142. Felber JP. From obesity to diabetes. Pathophysiological considerations. Int J Obes 1972; 16:937–952.
143. Jahoor F, Klein S, Wolfe R. Mechanism of regulation of glucose production by lipolysis in humans. Am J Physiol 1992; 262:E353-E358.
144. Jackson RL, McLean LR, Demel RA. Mechanism of action of lipoprotein lipase and hepatic triglyceride lipase. Am Heart J 1987; 113:551–554.
145. Pollare T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb 1991; 11:1192–1203.
146. Fujimoto WY, Leonetti DL, Newell-Morris L, Shuman WP, Wahl PW. Relationship of absence or presence of a family history of diabetes to body weight and body fat distribution in type 2 diabetes. Int J Obes 1990; 15:111–120.
147. Lemieux S, Després JP, Nadeau A, Prud'homme D, Tremblay A, Bouchard C. Heterogeneous glycaemic and insulinaemic responses to oral glucose in nondiabetic men: interactions between duration of obesity, body fat distribution and family history of diabetes mellitus. Diabetologia 1992; 35:653–659.
148. Peiris AN, Mueller RA, Struve MF, Smith GA, Kissebah AH. Relationship of androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women. J Clin Endocrinol Metab 1987; 64:162–169.
149. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab 1983; 57:304–310.
150. Kissebah AH, Evans DJ, Peiris A, Wilson CR. Endocrine characteristics in regional obesities: role of sex steroids. In: Vague J, Bjorntorp P, Guy-Grand B, eds. Metabolic Complications of Human Obesities Amsterdam: Elsevier Science, 1985:115–130.
151. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation is positively associated with insulin, glucose and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39:897–901.
152. Tchernof A, Després JP, Belanger A, Dupont A, Prud'homme D, Moorjani S, Lupien PJ, Labrie F. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism 1994; 4:513–519.
153. Tchernof A, Després JP, Dupont A, Belanger A, Nadeau A, Prud'homme D, Moorjani S, Lupien PJ, Labrie F. Importance of body fatness and adipose tissue distribution in the relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Diabetes Care 1995; 18:292–299.
154. Tchernof A, Després JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 2000; 32(11-12):526–536.
155. Tchernof A, Labrie F, Belanger A, Prud'homme D, Bouchard C, Tremblay A, Nadeau A, Després JP. Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 1997; 133(2): 235–244.
156. Tchernof A, Labrie F, Belanger A, Després JP. Obesity and metabolic complications: contribution of dehydro- epiandrosterone and other steroid hormones. J Endocrinol 1996; 150(suppl):S155-S164.
157. Brindley DN, Rolland Y. Possible connections between stress, diabetes, obesity, hypertension, and altered metabolism that may result in atherosclerosis. Clin Sci 1989; 77:453–461.
158. Brindley DN. Metabolic approaches to atherosclerosis: effect of gliclazide. Metabolism 1992; 41(suppl 1):20–24.
159. Brindley DN. Neuroendocrine regulation and obesity. Int J Obes 1992; 16:S73-S79.
160. Bjorntorp P. Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med 1991; 230:195–201.
161. Rebuflë-Scrive M, Lundholm K, Bjorntorp P. Glucocorticoid binding of human adipose tissue. Eur J Clin Invest 1985; 15:267–271.
162. Pedersen SB, Jonler M, Richelsen B. Characterization of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1994; 78:1354–1359.
163. Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L, Isaksson OG. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76(2):309–317.
164. Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol (Oxf) 1999; 50(1):1–15.
165. Snel YE, Brummer RJ, Doerga ME, Zelissen PM, Bakker CJ, Hendriks MJ, Koppeschaar HP. Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and a comparison with control subjects. Am J Clin Nutr 1995; 61(6):1290–1294.
166. Rosen T, Johannsson G, Johansson JO, Bengtsson BA. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. A review paper. Horm Res 1995; 43(1-3):93–99.
167. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000; 133(2):111–122.
168. Seidell JC, Oosterlee A, Thijssen MAO, Burema J, Deurenberg P, Hautvast JGAJ, Ruijs JHJ. Assessment of intra-abdominal and subcutaneous abdominal fat: relation between anthropometry and computed tomography. Am J Clin Nutr 1987; 45:7–13.
169. Seidell JC, Oosterlee A, Deurenberg P, Hautvast JGAJ, Ruijs JHJ. Abdominal fat depots measured with computed tomography: effects of degree of obesity, sex and age. Eur J Clin Nutr 1988; 42:805–815.
170. Ferland M, Després JP, Tremblay A, Pinault S, Nadeau A, Moorjani S, Lupien PJ, Theriault G, Bouchard C. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Brit J Nutr 1989; 61:139–148.
171. Després JP, Prud'homme D, Pouliot MC, Tremblay A, Bouchard C. Estimation of deep abdominal fat accumulation from simple anthropometric measurements in men. Am J Clin Nutr 1991; 54:471–477.
172. Pouliot MC, Després JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73:460–468.
173. Folsom AR, Kaye SA, Sellers TA, Hong CP, Cerhan JR, Potter JD, Prineas RJ. Body fat distribution and 5-year risk of death in older women. JAMA 1993; 269: 483–487.
174. Stokes J, Garrison RJ, Kannel WB. The independent contributions of various indices of obesity to the 22- year incidence of coronary heart disease: the Framingham Heart Study. In: Vague J, Bjorntorp P, GuyGrand B, eds. Metabolic Complications of Human Obesities. Amsterdam: Elsevier Science, 1985:49–57.
175. Terry RB, Page WF, Haskell WL. Waist/hip ratio, mass index and premature cardiovascular disease mortality in US army veteran during a twenty-three year follow-up study. Int J Obes 1992; 16:417–423.
176. Sjostrom L, Larsson B, Backman L, Bengtsson C, Bouchard C, Dahlgren S, Hallgren P, Jonsson E, Karls son J, Lapidus L. Swedish Obese Subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obes 1992; 16:465–479.
177. Després JP. Drug treatment for obesity. We need more studies in men at higher risk of coronary events. BMJ 2001; 322(7299):1379–1380.
178. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322(7288):716–720.
179. Després JP, Lemieux S, Lamarche B, Prud'homme D, Moorjani S, Brun LD, Gagne C, Lupien PJ. The insulin-resistance syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes 1995; 19(suppl):S76-S86.